Erythropoietin: High profile, high scrutiny

Journal of Clinical Oncology

Volumn 25, Issue 9, 2007, Pages 1021-1023

  Crawford, Jeffrey ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EDITORIAL; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG SMALL CELL CANCER; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; THROMBOSIS; CHEMICALLY INDUCED DISORDER; METHODOLOGY; MORTALITY; NEOPLASM; NOTE; QUALITY OF LIFE; RISK ASSESSMENT; TREATMENT OUTCOME;

ANEMIA; ANTINEOPLASTIC AGENTS; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 34047227171     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.8153     Document Type: Editorial

References (24)

1. Eschbach JW, Ergrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
2. Henry DH, Abels RI: Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies. Semin Oncol 21:21-28, 1994 (suppl 3)
3. Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218-1234, 1997
4. Demetri GD, Kris M, Wade J, et al: Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 16:3412-3425, 1998
5. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882, 2001
6. Cella D: Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol 25:43-46, 1998
7. Littlewood TJ, Bajett E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001
8. Crawford J, Cella D, Cleeland CS, et al: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 94:888-895, 2002
9. National Comprehensive Cancer Network: version 2. 2006, www.nccn.org.
10. Bohlius J, Wilson J, Seidenfeld J, et al: Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708-714, 2006
11. Steensma DP, Loprinzi CL: Erythropoietin use in cancer patients: A matter of life and death? J Clin Oncol 23:5865-5868, 2005
12. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 23:5960-5972, 2005
13. Steensma D, Loprinzi C: Epoetin alfa and darbepoetin alfa go head to head. J Clin Oncol 24:2233-2236, 2006
14. Glaspy J, Vadhan-Raj S, Patel R, et al: Randomized comparison of every 2 weeks darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 20030125 Study Group Trial. J Clin Oncol 24:2290-2297, 2006
15. Lai SY, Grandis JR: Understanding the presence and function of erythropoietin receptors on cancer cells. J Clin Oncol 24:4675-4676, 2006
16. Henke M, Mattern D, Pepe M, et al: Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24:4708-4713, 2006
17. Wright JR, Yee CU, Julian JA, et al: A randomized, double-blind, placebo-controlled trial of erythropoietin to treat patients with non-small cell lung cancer and disease related anemia. J Clin Oncol 25:1027-1032, 2007
18. Crawford J, Francisco R, Perry M, et al: A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol 3:210-220, 2007
19. Vansteenkiste J, Pirker R, Massuti B, et al: Double-blind, placebo-controlled, randomized Phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211-1220, 2002
20. Bohlius J, Langensiepen S, Schwarzer G, et al: Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis. J Natl Cancer Inst 97:489-498, 2005
21. Grote T, Allen A, Castillo R, et al: Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 23:9377-9386, 2005
22. Glaspy JA: Cancer patient survival and erythropoietin. J Natl Compr Canc Netw 3:796-804, 2005
23. Crawford J: Erythropoiesis-stimulating protein support and survival. Oncology 20:39-43, 2006 (suppl 6)
24. Goldberg P: Study finds more deaths on Aranesp arm in cancer anemia study, no benefit seen [newsletter]. The Cancer Letter 33:1, 2007